

Serial No. 08/605,567  
Docket No. 16955DIVCONCIP(AP)

2

wherein X is a radical selected from the group consisting of -OR<sup>4</sup> and -N(R<sup>4</sup>)<sub>2</sub>  
wherein R<sup>4</sup> is selected from the group consisting of hydrogen, a lower alkyl  
radical having from one to six

T340X

carbon atoms, R<sup>5</sup>-C- or R<sup>5</sup>-O-C- wherein R<sup>5</sup> is a lower alkyl radical having  
from one to six carbon atoms; Z is =O or represents 2 hydrogen radicals; Y' is  
Cl or trifluoromethyl, provided however, that when Z is =O, then X is not -  
OR<sup>4</sup> and the 9- and/or 11- and/or 15 esters, thereof.

C

Claim 7 (Amended) The method of claim 5 wherein Z is =O and X is  
selected from the group consisting of NH<sub>2</sub> [or OCH<sub>3</sub>].

Claim 8 (Twice Amended) The method of claim 5 wherein [Y<sup>1</sup>] is Cl  
or trifluoromethyl,] Z is =O and X is selected from the group consisting of  
[alkoxy and] amido radicals.

E

Cancel claim 8.

B<sup>2</sup>

Claim 9 (Amended) The method of claim [7] wherein X is selected  
from the group consisting of NH<sub>2</sub> and OCH<sub>3</sub>.

Cancel claim 10.

Cancel claims 21 through 45.

#### REMARKS

As a result of this amendment, claims 1-4, 8, 10 and 21 through 45 have been cancelled, without prejudice. (Such claims are believed to be patentable to the applicants, but may be subject to an interference with U.S. Patent Number 5,510,383 to Bishop et al. The remaining claims 5-7, 9, 11-20 and 46-51 are also believed to be patentable and not subject to interference with the Bishop et al Patent).

AU

Serial No. 08/605,567  
Docket No. 16955DIVCONCIP(AP)

3

Of the remaining claims, claims 5-7, 9 and 46-51 are limited to the lowering intraocular pressure (IOP) or treating glaucoma with certain non-acidic cyclopentane heptan(en)oic acid, 2-cycloalkyl or arylalkyl derivatives wherein the 2-substituent (or omega chain) does not include an O-alkylene linking moiety. Claims 11 through 20 are not so limited but are directed to treating other diseases and conditions that are not lowering IOP or treating glaucoma.

It is believed that such remaining claims are patentable over the art cited by the applicants and the Examiner. The cancelled claims will be filed in a continuation application for the purpose of provoking an interference with the Bishop Patent.

Respectfully Submitted,



Robert J. Baran  
Registration No. 25,806  
Telephone: 714/246-4669  
Telecopier: 714/246-4249

ROBERT J. BARAN  
Legal Department (T2-2E)  
Allergan, Inc.  
2525 Dupont Drive  
Irvine, CA 92612-1599

CERTIFICATE OF MAILING

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE WITH SUFFICIENT POSTAGE AS FIRST-CLASS MAIL IN AN ENVELOPE ADDRESSED TO: BOX ISSUE FEE ASSISTANT COMMISSIONER FOR PATENTS, WASHINGTON, D.C. 20231 ON 6/16/97 (Date)

Name of person making deposit: Bonnie Ferguson

Signature: Bonnie Ferguson Date 6/16/97